Dr. Wael Mohamed, BSc, MMSc, MD, PhD, FAAS, is Professor, Basic Medical Science Department at the International Islamic University Malaysia (IIUM). He specializes in translational brain research and the development of novel treatments for Alzheimer’s Disease and Parkinson’s Disease.

• Section I. Understanding PD and related movement disorders1. Neuroinflammation, glymphatic system, and Parkinson's disease2. Pharmacotherapy of PD and related movements disorders and their limitations3. Diagnosis and biomarkers of Parkinson's disease and related movement disorders4. OMICS and bioinformatics in Parkinson disease and related movements disorders5. Modeling Parkinson's disease with the alpha-synuclein protein6. α-Synuclein seeding assay and analysisSection II. Mammalian models of Parkinson's disease7. SHH, nurr1, pitx3, and en1 models for Parkinson's disease8. Stem cell for PD: Technical considerations9. Deep brain stimulation using animal models of Parkinson's disease10. The MitoPark mouse model of Parkinson's disease11. The beta-sitosterol beta-D-glucoside (BSSG) rat model of Parkinson's diseaseSection III. Invertebrate models of Parkinson's disease12. SCA1 zebrafish model13. Various zebrafish models of Parkinson's disease: What gives us hope14. Drosophila PD model15. Caenorhabditis elegans models of tauopathy16. LRRK2 in Caenorhabditis elegans modelSection IV. Ethics and regulations related to translational PD models17. Confounding factors for validation of PD models18. Neurobehavioral characterization of PD models19. Ethical regulations for induction and validation of PD models20. The OMICS and PD models: Hopes or hypes21. Parkinson's disease from an Ayurveda perspective: Opportunities and challenges for further research

Dr. Wael Mohamed, BSc, MMSc, MD, PhD, FAAS, is Professor, Basic Medical Science Department at the International Islamic University Malaysia (IIUM). He specializes in translational brain research and the development of novel treatments for Alzheimer’s Disease and Parkinson’s Disease.

• Section I. Understanding PD and related movement disorders1. Neuroinflammation, glymphatic system, and Parkinson's disease2. Pharmacotherapy of PD and related movements disorders and their limitations3. Diagnosis and biomarkers of Parkinson's disease and related movement disorders4. OMICS and bioinformatics in Parkinson disease and related movements disorders5. Modeling Parkinson's disease with the alpha-synuclein protein6. α-Synuclein seeding assay and analysisSection II. Mammalian models of Parkinson's disease7. SHH, nurr1, pitx3, and en1 models for Parkinson's disease8. Stem cell for PD: Technical considerations9. Deep brain stimulation using animal models of Parkinson's disease10. The MitoPark mouse model of Parkinson's disease11. The beta-sitosterol beta-D-glucoside (BSSG) rat model of Parkinson's diseaseSection III. Invertebrate models of Parkinson's disease12. SCA1 zebrafish model13. Various zebrafish models of Parkinson's disease: What gives us hope14. Drosophila PD model15. Caenorhabditis elegans models of tauopathy16. LRRK2 in Caenorhabditis elegans modelSection IV. Ethics and regulations related to translational PD models17. Confounding factors for validation of PD models18. Neurobehavioral characterization of PD models19. Ethical regulations for induction and validation of PD models20. The OMICS and PD models: Hopes or hypes21. Parkinson's disease from an Ayurveda perspective: Opportunities and challenges for further research

Dr. Wael Mohamed, BSc, MMSc, MD, PhD, FAAS, is Professor, Basic Medical Science Department at the International Islamic University Malaysia (IIUM). He specializes in translational brain research and the development of novel treatments for Alzheimer’s Disease and Parkinson’s Disease.

• Section I. Understanding PD and related movement disorders1. Neuroinflammation, glymphatic system, and Parkinson's disease2. Pharmacotherapy of PD and related movements disorders and their limitations3. Diagnosis and biomarkers of Parkinson's disease and related movement disorders4. OMICS and bioinformatics in Parkinson disease and related movements disorders5. Modeling Parkinson's disease with the alpha-synuclein protein6. α-Synuclein seeding assay and analysisSection II. Mammalian models of Parkinson's disease7. SHH, nurr1, pitx3, and en1 models for Parkinson's disease8. Stem cell for PD: Technical considerations9. Deep brain stimulation using animal models of Parkinson's disease10. The MitoPark mouse model of Parkinson's disease11. The beta-sitosterol beta-D-glucoside (BSSG) rat model of Parkinson's diseaseSection III. Invertebrate models of Parkinson's disease12. SCA1 zebrafish model13. Various zebrafish models of Parkinson's disease: What gives us hope14. Drosophila PD model15. Caenorhabditis elegans models of tauopathy16. LRRK2 in Caenorhabditis elegans modelSection IV. Ethics and regulations related to translational PD models17. Confounding factors for validation of PD models18. Neurobehavioral characterization of PD models19. Ethical regulations for induction and validation of PD models20. The OMICS and PD models: Hopes or hypes21. Parkinson's disease from an Ayurveda perspective: Opportunities and challenges for further research